Please use a minimum of three unique search words
Our search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Abasaglar ® (basal insulin glargine)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information.For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).
How are patients transitioned from another basal insulin to Abasaglar® (insulin glargine)?
If transitioning from another basal insulin to Abasaglar, the recommended initial Abasaglar dose is based on the insulin therapy that is being discontinued.
UK_cFAQ_BIV049_TRANSITION_TABLE
en-GB
Detailed Information
If transitioning patients from another basal insulin to Abasaglar therapy, the recommended initial dose of Abasaglar is based on the insulin therapy that is being discontinued (Transitioning From Another Basal Insulin to Abasaglar Therapy).
Reductions in the Abasaglar dose when transitioning from certain insulins will lower the likelihood of hypoglycemia.1,2
If transitioning from… |
To… |
Then, the recommended initial dose of Abasaglar … |
Example |
Lantus |
Abasaglar |
is the same as the Lantus dose. |
50 units of Lantus transitions to 50 units of Abasaglar |
Toujeo |
Abasaglar |
is 80% of the Toujeo dose. |
50 units of Toujeo transitions to 40 units of Abasaglar |
twice-daily NPH insulin |
once-daily Abasaglar |
is 70%-80% of the total daily NPH insulin dosage. |
25 units of NPH insulin every morning and 25 units of NPH insulin every evening, for a daily total of 50 units of NPH insulin, transitions to 35 units (70% of the NPH insulin total daily dose) or 40 units (80% of the NPH insulin total daily dose) of Abasaglar once daily |
an intermediate- or long-acting insulin other than Lantus |
Abasaglar |
may differ from the prior basal insulin dose and other concomitant antihyperglycemic medications may need to be adjusted. |
… |
Abbreviations: Abasaglar = Abasaglar® (insulin glargine injection) 100 units/mL; Lantus = Lantus® (insulin glargine injection) 100 units/mL; Toujeo = Toujeo® (insulin glargine injection) 300 units/mL.
References
1Abasaglar [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.
2Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Date of Last Review: 27 May 2021
Contact Lilly
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com
Available Mon - Fri, 10am - 4pm, excluding Bank Holidays